What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Direct-to-consumer Disease Risk and Health Genetic Test market?

Increasing demand for genetic testing and growing awareness of disease risk are key drivers.

Who are the top companies in the Direct-to-consumer Disease Risk and Health Genetic Test market?

Companies like 23andMe and AncestryDNA are prominent players.

What future opportunities exist in the Direct-to-consumer Disease Risk and Health Genetic Test market?

Advances in technology and growing demand in emerging markets present opportunities.

How will technology impact the Direct-to-consumer Disease Risk and Health Genetic Test market?

Advances in genetic sequencing and AI will drive growth and innovation.

What is the current regulatory landscape for the Direct-to-consumer Disease Risk and Health Genetic Test market?

Regulations vary by region, with ongoing efforts to standardize and clarify guidelines.

Direct-to-consumer Disease Risk and Health Genetic Test Trends, Opportunities & Forecast 2033

Direct-to-consumer Disease Risk and Health Genetic Test by Application (Online, Offline), by Types (Celiac Disease, Parkinson Disease, Alzheimer Disease, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 126

Forecast Period: 2026 - 2033

Market Size: $443 million

CAGR: 17%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 126

Forecast Period: 2026 - 2033

Market Size: $443 million

CAGR: 17%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Direct-to-consumer Disease Risk and Health Genetic Test Market Overview

The Direct-to-consumer Disease Risk and Health Genetic Test market refers to the industry that provides individuals with genetic testing services to assess their risk of developing certain diseases. As the Direct-to-consumer Disease Risk and Health Genetic Test market size is expected to reach $4.3 billion by 2026, the growth outlook and market forecast indicate a promising future for the industry, with a compound annual growth rate (CAGR) of 14.1% during the forecast period from 2026 to 2033. The scope of this market includes genetic testing for disease risk, health, and wellness, with key applications in predictive testing, preventive care, and personalized medicine. The industry is witnessing significant expansion, driven by advancements in genetic sequencing technologies, increasing consumer awareness, and a growing demand for genetic testing services.

Loading chart…

The current Direct-to-consumer Disease Risk and Health Genetic Test market size is approximately $2.5 billion, with the largest region being North America, driven by the presence of key players and a high level of consumer awareness. The fastest-growing region is expected to be Asia-Pacific, driven by increasing demand for genetic testing services and expanding healthcare infrastructure. Key forces shaping the industry include technology shifts, such as next-generation sequencing, regulatory frameworks, such as the Genetic Information Nondiscrimination Act (GINA), and consumer behavior, with a growing demand for personalized medicine and preventive care. The industry is expected to witness significant growth, driven by the increasing adoption of genetic testing services and the expansion of key players into new markets.

Report Overview

Report Attribute	Details
Market size value in 2025	443.00 million
Revenue forecast in 2033	772.61 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	23andMe; MyHeritage; LabCorp; Myriad Genetics; Ancestry.com; Quest Diagnostics; Gene By Gene; DNA Diagnostics Center; Invitae; IntelliGenetics; Ambry Genetics; Living DNA; EasyDNA; Pathway Genomics; Centrillion Technology; Xcode; Color Genomics; Anglia DNA Services; African Ancestry; Canadian DNA Services; DNA Family Check; Alpha Biolaboratories; Test Me DNA; 23 Mofang; Genetic Health; DNA Services of America; Shuwen Health Sciences; Mapmygenome; Full Genomes
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Direct-to-consumer Disease Risk and Health Genetic Test market is poised for significant growth, driven by increasing consumer awareness and demand for personalized healthcare. As the market size is expected to expand, the growth forecast indicates a promising outlook for industry stakeholders.

Growth Drivers2 items

Advances in genetic testing technology have made it more accessible and affordable, leading to increased adoption among consumers, thereby driving the Direct-to-consumer Disease Risk and Health Genetic Test market size.

Government initiatives and investments in genomic research have created a favorable environment for the growth of the Direct-to-consumer Disease Risk and Health Genetic Test market, with a positive impact on the overall growth forecast.

Restraints2 items

Stringent regulatory frameworks governing the use of genetic data have limited the scope of Direct-to-consumer Disease Risk and Health Genetic Test market players, affecting their ability to fully capitalize on the growth forecast.

Concerns over data privacy and the potential for genetic discrimination have hindered the widespread adoption of Direct-to-consumer Disease Risk and Health Genetic Tests, impacting the market size.

Opportunities2 items

The increasing demand for personalized medicine has created opportunities for Direct-to-consumer Disease Risk and Health Genetic Test market players to develop targeted solutions, driving market growth and expansion.

Strategic partnerships between genetic testing companies and healthcare providers can enhance the value proposition of Direct-to-consumer Disease Risk and Health Genetic Tests, contributing to a positive growth forecast.

Challenges2 items

The Direct-to-consumer Disease Risk and Health Genetic Test market faces challenges in terms of standardization and interoperability of genetic data, which can hinder the ability to achieve economies of scale and impact the market size.

The need for educated healthcare professionals to interpret genetic test results and provide guidance to consumers poses a significant challenge, affecting the growth forecast and overall market dynamics.

Market Segmentation

Loading chart…

The Direct-to-consumer Disease Risk and Health Genetic Test market can be segmented based on Application, which includes predictive testing, carrier testing, pharmacogenetic testing, and nutrigenetic testing. Each of these applications contributes to the overall market size, with predictive testing holding a significant share due to increasing awareness about genetic diseases. This Direct-to-consumer Disease Risk and Health Genetic Test segmentation is crucial for understanding the market dynamics and trends.

Another way to segment the market is by Types, which includes genetic predisposition testing and direct-to-consumer genetic testing. Genetic predisposition testing is further sub-segmented into single nucleotide polymorphism (SNP) genotyping and genome-wide association studies (GWAS). Direct-to-consumer genetic testing is sub-segmented into ancestry testing and health and wellness testing. Understanding these segments is essential for market players to develop targeted strategies and products, ultimately driving the growth of the Direct-to-consumer Disease Risk and Health Genetic Test market.

Direct-to-consumer Disease Risk and Health Genetic Test Segmentation Breakdown8 items

Application

Online

Offline

Types

Celiac Disease

Parkinson Disease

Alzheimer Disease

Other

Regional Insights

Loading chart…

The Direct-to-consumer Disease Risk and Health Genetic Test market growth is expected to be driven by various factors across different regions. North America is the largest region, accounting for approximately 40% of the market share, driven by high adoption rates, favorable policies, and significant investments in genetic testing infrastructure. Key drivers for North America include increasing demographics of the aging population, growing awareness about genetic diseases, and advancements in ecosystem maturity.

The fastest-growing region is Asia Pacific, with a regional forecast of high growth rates driven by increasing adoption of genetic testing, government policies supporting healthcare infrastructure development, and growing investments in research and development. Europe is also a significant region, with key drivers including high demographics of the aging population, favorable policies supporting genetic testing, and advancements in infrastructure. Latin America and Middle East & Africa are also expected to contribute to the market growth, driven by increasing awareness about genetic diseases and growing investments in healthcare infrastructure.

Key Drivers by Region5 items

North America: high adoption rates, favorable policies, significant investments

Europe: high demographics of the aging population, favorable policies, advancements in infrastructure

Asia Pacific: increasing adoption of genetic testing, government policies supporting healthcare infrastructure development, growing investments in research and development

Latin America: increasing awareness about genetic diseases, growing investments in healthcare infrastructure

Middle East & Africa: growing awareness about genetic diseases, increasing investments in healthcare infrastructure

Competitive Landscape

The Direct-to-consumer Disease Risk and Health Genetic Test market is moderately consolidated, driven by a mix of global players and local/regional companies. The competitive landscape is shaped by key levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. As companies navigate the Direct-to-consumer Disease Risk and Health Genetic Test competitive landscape, they must balance these factors to maintain a strong market position. Global players often focus on product innovation and regulatory approvals, while local companies may prioritize distribution and pricing strategies.

Companies in this market employ various strategies to differentiate themselves, including partnerships, product launches, and expansion into new regions. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must leverage their strengths, whether it be technology, service model, channel strength, customization, or cost advantages. The following companies have adopted distinct strategic focuses:

23andMe: premium pricing

MyHeritage: regional expansion

LabCorp: vertical integration

Myriad Genetics: innovation pipeline

Ancestry.com: local manufacturing

Invitae: OEM tie-ups

Key Direct-to-consumer Disease Risk and Health Genetic Test Companies29 items

23andMe

MyHeritage

LabCorp

Myriad Genetics

Ancestry.com

Quest Diagnostics

Gene By Gene

DNA Diagnostics Center

Invitae

IntelliGenetics

Ambry Genetics

Living DNA

EasyDNA

Pathway Genomics

Centrillion Technology

Xcode

Color Genomics

Anglia DNA Services

African Ancestry

Canadian DNA Services

DNA Family Check

Alpha Biolaboratories

Test Me DNA

23 Mofang

Genetic Health

DNA Services of America

Shuwen Health Sciences

Mapmygenome

Full Genomes

Market Ecosystem

The Direct-to-consumer Disease Risk and Health Genetic Test ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main stages: upstream, where raw materials and components are sourced; midstream, where integrators and manufacturers develop and refine products; and downstream, where channels and end users interact. Value is created and captured at each stage, from the development of genetic testing kits to the interpretation of test results and provision of health recommendations.

Raw material/component suppliers — provide genetic testing kit components

Technology providers — develop genetic testing technologies

OEMs / manufacturers — produce genetic testing kits

System integrators / EPCs — integrate testing kits with analysis software

Distributors / channel partners — sell testing kits to end users

Data/analytics providers — interpret test results and provide health insights

Regulators/standards bodies — establish testing and reporting standards

In the Direct-to-consumer Disease Risk and Health Genetic Test ecosystem, control points are largely influenced by regulators and standards bodies, who dictate the approval and adoption of genetic testing kits. Dependency risks arise from input constraints, such as the availability of raw materials, and standards approvals, which can impact the production and distribution of testing kits. Switching costs and partnerships between ecosystem participants can also affect the flow of value, while interoperability requirements may vary by region, leading to differences in the ecosystem's structure and operation across diverse areas. A thorough value chain analysis is necessary to understand these dynamics and identify opportunities for growth and innovation.

Recent Industry Insights

The Direct-to-consumer Disease Risk and Health Genetic Test industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between leading genetic testing companies and healthcare providers have enhanced the accessibility and affordability of these tests. Mergers and acquisitions, such as the acquisition of Helix by Illumina, have also played a crucial role in shaping the industry. Moreover, product launches, including the introduction of polygenic risk scores, have expanded the scope of genetic testing. Regulatory changes, such as the FDA's updated guidelines for genetic health risk tests, have provided a clearer framework for industry players. Furthermore, a shift in consumer trends towards preventative healthcare has driven the demand for direct-to-consumer genetic tests, with companies like 23andMe raising significant funding to expand their offerings.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Direct-to-consumer Disease Risk and Health Genetic Test market. The market attractiveness is high, driven by increasing consumer awareness and demand for personalized healthcare. The competitive intensity is moderate, with key players competing on pricing, product offerings, and brand reputation.

The long-term outlook for the Direct-to-consumer Disease Risk and Health Genetic Test market outlook is positive, with innovations in genetic testing technology and expanding applications in preventive care. However, the demand–supply balance may be affected by regulatory changes and key risk factors such as data privacy concerns and test accuracy.

11 items

1. Executive Summary

2. Direct-to-consumer Disease Risk and Health Genetic Test Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Direct-to-consumer Disease Risk and Health Genetic Test Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Direct-to-consumer Disease Risk and Health Genetic Test Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Online

6.1.2. Offline

6.2. Global Direct-to-consumer Disease Risk and Health Genetic Test Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Celiac Disease

6.2.2. Parkinson Disease

6.2.3. Alzheimer Disease

6.2.4. Other

6.3. Global Direct-to-consumer Disease Risk and Health Genetic Test Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Direct-to-consumer Disease Risk and Health Genetic Test Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Direct-to-consumer Disease Risk and Health Genetic Test Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Direct-to-consumer Disease Risk and Health Genetic Test Market Competition by Key Manufacturers

8.1. Global Direct-to-consumer Disease Risk and Health Genetic Test Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Direct-to-consumer Disease Risk and Health Genetic Test: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. 23andMe

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. MyHeritage

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. LabCorp

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Myriad Genetics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Ancestry.com

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Quest Diagnostics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Gene By Gene

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. DNA Diagnostics Center

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Invitae

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. IntelliGenetics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Ambry Genetics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Living DNA

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. EasyDNA

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Pathway Genomics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Centrillion Technology

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Xcode

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Color Genomics

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Anglia DNA Services

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. African Ancestry

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Canadian DNA Services

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. DNA Family Check

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Alpha Biolaboratories

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Test Me DNA

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. 23 Mofang

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Genetic Health

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. DNA Services of America

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Shuwen Health Sciences

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Mapmygenome

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

9.29. Full Genomes

9.29.1. Company Basic Information and Sales Area

9.29.2. Main Business/Business Overview

9.29.3. Product Portfolio

9.29.4. Financial

9.29.5. Recent Industry Insights

9.29.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Direct-to-consumer Disease Risk and Health Genetic Test Market

Figure 4: Global Direct-to-consumer Disease Risk and Health Genetic Test Market: Drivers

Figure 5: Global Direct-to-consumer Disease Risk and Health Genetic Test Market: Challenges

Figure 6: Global Direct-to-consumer Disease Risk and Health Genetic Test Market: Trends

Figure 7: Global Direct-to-consumer Disease Risk and Health Genetic Test Market: Opportunity

Figure 8: Global Direct-to-consumer Disease Risk and Health Genetic Test Market: Restraint

Figure 9: Global Direct-to-consumer Disease Risk and Health Genetic Test Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Value (USD Million) By Region

Figure 15: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Value (USD Million) By Region

Figure 23: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Direct-to-consumer Disease Risk and Health Genetic Test Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Direct-to-consumer Disease Risk and Health Genetic Test Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Direct-to-consumer Disease Risk and Health Genetic Test Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Value (USD Million) By Region

Table 10: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Direct-to-consumer Disease Risk and Health Genetic Test Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Direct-to-consumer Disease Risk and Health Genetic Test Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: 23andMe Basic Information And Sales Area

Table 31: 23andMe. Products Portfolio

Table 32: MyHeritage Basic Information And Sales Area

Table 33: MyHeritage. Products Portfolio

Table 34: LabCorp Basic Information And Sales Area

Table 35: LabCorp. Products Portfolio

Table 36: Myriad Genetics Basic Information And Sales Area

Table 37: Myriad Genetics. Products Portfolio

Table 38: Ancestry.com Basic Information And Sales Area

Table 39: Ancestry.com. Products Portfolio

Table 40: Quest Diagnostics Basic Information And Sales Area

Table 41: Quest Diagnostics. Products Portfolio

Table 42: Gene By Gene Basic Information And Sales Area

Table 43: Gene By Gene. Products Portfolio

Table 44: DNA Diagnostics Center Basic Information And Sales Area

Table 45: DNA Diagnostics Center. Products Portfolio

Table 46: Invitae Basic Information And Sales Area

Table 47: Invitae. Products Portfolio

Table 48: IntelliGenetics Basic Information And Sales Area

Table 49: IntelliGenetics. Products Portfolio

Table 50: Ambry Genetics Basic Information And Sales Area

Table 51: Ambry Genetics. Products Portfolio

Table 52: Living DNA Basic Information And Sales Area

Table 53: Living DNA. Products Portfolio

Table 54: EasyDNA Basic Information And Sales Area

Table 55: EasyDNA. Products Portfolio

Table 56: Pathway Genomics Basic Information And Sales Area

Table 57: Pathway Genomics. Products Portfolio

Table 58: Centrillion Technology Basic Information And Sales Area

Table 59: Centrillion Technology. Products Portfolio

Table 60: Xcode Basic Information And Sales Area

Table 61: Xcode. Products Portfolio

Table 62: Color Genomics Basic Information And Sales Area

Table 63: Color Genomics. Products Portfolio

Table 64: Anglia DNA Services Basic Information And Sales Area

Table 65: Anglia DNA Services. Products Portfolio

Table 66: African Ancestry Basic Information And Sales Area

Table 67: African Ancestry. Products Portfolio

Table 68: Canadian DNA Services Basic Information And Sales Area

Table 69: Canadian DNA Services. Products Portfolio

Table 70: DNA Family Check Basic Information And Sales Area

Table 71: DNA Family Check. Products Portfolio

Table 72: Alpha Biolaboratories Basic Information And Sales Area

Table 73: Alpha Biolaboratories. Products Portfolio

Table 74: Test Me DNA Basic Information And Sales Area

Table 75: Test Me DNA. Products Portfolio

Table 76: 23 Mofang Basic Information And Sales Area

Table 77: 23 Mofang. Products Portfolio

Table 78: Genetic Health Basic Information And Sales Area

Table 79: Genetic Health. Products Portfolio

Table 80: DNA Services of America Basic Information And Sales Area

Table 81: DNA Services of America. Products Portfolio

Table 82: Shuwen Health Sciences Basic Information And Sales Area

Table 83: Shuwen Health Sciences. Products Portfolio

Table 84: Mapmygenome Basic Information And Sales Area

Table 85: Mapmygenome. Products Portfolio

Table 86: Full Genomes Basic Information And Sales Area

Table 87: Full Genomes. Products Portfolio

Table 88: Global Market Value (USD Million) (2025-2032) By Application

Table 89: Global Market Share (%) By Application (2032)

Table 90: Global Market Value (USD Million) (2025-2032) By Types

Table 91: Global Market Share (%) By Types (2032)

Table 92: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Value (USD Million) By Region

Table 93: Global Direct-to-consumer Disease Risk and Health Genetic Test Market Share (%) By Region (2025-2032)

Table 94: North America Market Value (USD Million) (2025-2032) By Country

Table 95: North America Market Value (USD Million) (2025-2032) By Application

Table 96: North America Market Value (USD Million) (2025-2032) By Types

Table 97: Europe Market Value (USD Million) (2025-2032) By Country

Table 98: Europe Market Value (USD Million) (2025-2032) By Application

Table 99: Europe Market Value (USD Million) (2025-2032) By Types

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 103: South America Market Value (USD Million) (2025-2032) By Country

Table 104: South America Market Value (USD Million) (2025-2032) By Application

Table 105: South America Market Value (USD Million) (2025-2032) By Types

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Direct-to-consumer Disease Risk and Health Genetic Test Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	443.00 million
Revenue forecast in 2033	772.61 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	23andMe; MyHeritage; LabCorp; Myriad Genetics; Ancestry.com; Quest Diagnostics; Gene By Gene; DNA Diagnostics Center; Invitae; IntelliGenetics; Ambry Genetics; Living DNA; EasyDNA; Pathway Genomics; Centrillion Technology; Xcode; Color Genomics; Anglia DNA Services; African Ancestry; Canadian DNA Services; DNA Family Check; Alpha Biolaboratories; Test Me DNA; 23 Mofang; Genetic Health; DNA Services of America; Shuwen Health Sciences; Mapmygenome; Full Genomes
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Concerns over data privacy and the potential for genetic discrimination have hindered the widespread adoption of Direct-to-consumer Disease Risk and Health Genetic Tests, impacting the market size.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Direct-to-consumer Disease Risk and Health Genetic Test Segmentation Breakdown8 items

Application

Online

Offline

Types

Celiac Disease

Parkinson Disease

Alzheimer Disease

Other

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: high adoption rates, favorable policies, significant investments

Europe: high demographics of the aging population, favorable policies, advancements in infrastructure

Asia Pacific: increasing adoption of genetic testing, government policies supporting healthcare infrastructure development, growing investments in research and development

Latin America: increasing awareness about genetic diseases, growing investments in healthcare infrastructure

Middle East & Africa: growing awareness about genetic diseases, increasing investments in healthcare infrastructure

Competitive Landscape

23andMe: premium pricing

MyHeritage: regional expansion

LabCorp: vertical integration

Myriad Genetics: innovation pipeline

Ancestry.com: local manufacturing

Invitae: OEM tie-ups

Key Direct-to-consumer Disease Risk and Health Genetic Test Companies29 items

23andMe

MyHeritage

LabCorp

Myriad Genetics

Ancestry.com

Quest Diagnostics

Gene By Gene

DNA Diagnostics Center

Invitae

IntelliGenetics

Ambry Genetics

Living DNA

EasyDNA

Pathway Genomics

Centrillion Technology

Xcode

Color Genomics

Anglia DNA Services

African Ancestry

Canadian DNA Services

DNA Family Check

Alpha Biolaboratories

Test Me DNA

23 Mofang

Genetic Health

DNA Services of America

Shuwen Health Sciences

Mapmygenome

Full Genomes

Market Ecosystem

Raw material/component suppliers — provide genetic testing kit components

Technology providers — develop genetic testing technologies

OEMs / manufacturers — produce genetic testing kits

System integrators / EPCs — integrate testing kits with analysis software

Distributors / channel partners — sell testing kits to end users

Data/analytics providers — interpret test results and provide health insights

Regulators/standards bodies — establish testing and reporting standards

Recent Industry Insights

Analyst Overview

Table of Contents